Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederthelancet.com
The Lancet
Get the latest updates from The Lancet directly as they happen.
Follow now 93 followers
Latest posts
Last updated 1 day ago
Nivolumab plus ipilimumab in hepatocellular carcinoma
1 day ago
Hepatocellular carcinoma is the third leading cause of cancer-related mortality worldwide and...
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
1 day ago
Nivolumab plus ipilimumab showed a significant overall survival benefit versus lenvatinib or...
Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial
2 days ago
Sofosbuvir–daclatasvir was non-inferior to sofosbuvir–velpatasvir. High efficacy was seen with novel strategies...
Mapping the unseen: global prevalence of childhood sexual violence
2 days ago
Sexual violence against children (SVAC) is a global public health problem that...
Prevalence of sexual violence against children and age at first exposure: a global analysis by location, age, and sex (1990–2023)
2 days ago
The prevalence of SVAC is extremely high for both females and males...
Improved hypertension care requires measurement and management in health facilities, not mass screening
2 days ago
Improved hypertension control can save millions of lives, but mass hypertension screening...
Innovative strategies to enhance access to HCV therapy
2 days ago
As of 2022, an estimated 50 million people globally were infected with...
Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
3 days ago
Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral...
Obicetrapib–ezetimibe combination therapy for patients with atherosclerotic cardiovascular disease
3 days ago
Cardiovascular disease remains a leading cause of morbidity and mortality worldwide, with...
The regulatory rollercoaster continues—EMA refuses donanemab
7 days ago
In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment...
The Global North is increasingly unsafe for global health meetings
7 days ago
American civil rights activist Maya Angelou once wrote, “prejudice is a burden...